
SentiSense
Ctrl+K
Quick tip: Press
to search stocks
P
PODD
Insulet Corporation
$237.01
-3.93 (-1.63%)
Summary
Stories
News
Metrics
Fundamentals
Current Market Valuation
Current Price
$237.01
Live market price
P/E (TTM)
67.91
EPS: $3.49
P/S (TTM)
6.16
Price to Sales
TTM Quarters
4
Quarters included in TTM
Updated: 3/8/2026, 10:24:21 PM
Historical Trends
Range:
Revenue Over Time
Net Income Over Time
Short Interest (% of Float) Over Time
Short Interest
1.5M
% of Float
2.2%
Days to Cover
1.5
Avg Daily Vol
995K
Historical income statement data up to 5 years
Historical SEC Filings
Report Period
Debt/Equity
0.66
Leverage ratio
ROE (TTM)
16.31%
Return on equity
Income Statement
Revenue
$2.71B
Cost of Revenue
$768.20M
Gross Profit
$1.94B
Operating Income
$473.80M
Net Income
$247.10M
EPS (Quarter)
$3.48
EPS (TTM)
--
Balance Sheet
Total Assets
$3.19B
Total Liabilities
$1.68B
Shareholders' Equity
$1.52B
Current Assets
$1.91B
Current Liabilities
$680.10M
Cash & Equivalents
--
Long-Term Debt
--
Cash Flow
Operating Cash Flow
$569.30M
Investing Cash Flow
$-222.70M
Financing Cash Flow
$-595.30M
Free Cash Flow
$346.60M
Profitability Margins
Gross Margin
71.63%
Operating Margin
17.50%
Net Profit Margin
9.12%
ROA (TTM)
7.75%
ROE (TTM)
16.31%
Data source: Polygon.io
Last updated: 3/8/2026, 10:24:21 PM
Company Profile
Symbol
PODD
Market Cap
$16.68B
IPO Date
May 15, 2007
CEO
--
Employees
5,400
Sector
--
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Country
United States
Exchange
--
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Read More